ACT Onco® + Report

PATIENT		
Identifier: 詹子文		Patient ID: 46075212
Date of Birth: Jul 20, 1970		Gender: Male
Diagnosis: Melanoma		
ORDERING PHYSICIAN		
Name: 楊慕華醫師		Tel: 886-228712121
Facility: 臺北榮總		
Address: 臺北市北投區石牌路二段 201 號		
SPECIMEN		
Specimen ID: S11290163A	Collection site: Stomach	Type: FFPE tissue
Date received: Feb 15, 2023	Lab ID: AA-23-00943	D/ID: NA

ABOUT ACTOnco®+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) (≤ 15 nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

SUMMARY FOR ACTIONABLE VARIANTS

VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	Resistant	
Not detected			

VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
Not detected		

Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criterial for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

ACT Onco® + Report

TESTING RESULTS

VARIANT(S) WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
Not detected		

- Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Chr11	*ATM*	Heterozygous deletion	1
Chr5	*TERT*	Amplification	7
Chr7	*CARD11*	Amplification	8

- Fusions

Fusion Gene & Exon	Transcript ID
No fusion gene detected in this sample	

- Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	< 1 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

Note:
- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 40% tumor purity.
- For more therapeutic agents which are possibly respond to heterozygous deletion of genes listed above, please refer to APPENDIX for more information.
- TMB was calculated by using the sequenced regions of ACTOnco®+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at ≥ 7.5 mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is < 30%.

ACT Onco® + Report

THERAPEUTIC IMPLICATIONS

TARGETED THERAPIES

Not Applicable.

IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

- Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
Not detected	

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

OTHERS

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to other therapies.

Note:
Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

ACT Onco® + Report

VARIANT INTERPRETATION

ATM Heterozygous deletion

Biological Impact

The ataxia-telangiectasia mutated protein kinase (ATM) gene encodes a PI3K-related serine/threonine protein kinase involved in genomic integrity maintenance and plays central roles in DNA double-strand break (DSB) repair, which can be induced by ionizing radiation, chemotherapy drugs, or oxidative stress[1]. ATM is a well-characterized tumor suppressor gene, hereditary mutations and haploinsufficiency of ATM result in markedly increased susceptibility to a variety of cancer types[2][3][4][5][6]. Results from a case-cohort study of colorectal cancer and cancer-free control individuals suggested that germline pathogenic mutations in ATM and PALB2 should be added to established CRC risk genes as part of standard tumor genetic testing panels[7]. ATM is among the most commonly aberrant genes in sporadic cancers. Somatic ATM aberrations are frequently observed in hematologic malignancies[8][9][10][11]and a board range of tumors such as prostate cancer[12], head and neck squamous cell carcinoma (HNSCC)[13], pancreatic cancer[14], lung adenocarcinoma[15], breast cancer[16], and ovarian cancer[3].

Therapeutic and prognostic relevance

In May 2020, the U.S. FDA approved olaparib for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in homologous recombination repair (HRR) genes, including BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54L, and progressed following prior treatment with enzalutamide or abiraterone acetate (NCT02987543)[17].

In a phase II trial (TOPARP-A; NCT01682772), 3 out of 4 metastatic prostate cancer patients harboring only ATM inactivating mutations responded to olaparib treatment[18]. Also, the phase II TOPARP-B trial (NCT01682772) demonstrated that olaparib treatment resulted in a RECIST 1.1 or PSA50 response rate of 10.5% (2/12) and a composite overall response rate of 36.8% (7/19) in prostate cancer patients harboring deleterious ATM mutations[19].In another randomized, double-blind phase II trial in Asian patients with metastatic gastric cancer has shown that addition of olaparib to paclitaxel significantly increased the OS in both the overall population and patients with low or undetectable ATM protein expression (NCT01063517)[20]. However, in the subsequent phase III trial (GOLD; NCT01924533), addition of olaparib to paclitaxel did not significantly improve OS in the overall or the ATM-negative population of Asian gastric cancer patients[21]. Besides, in a phase II trial (TBCRC 048; NCT03344965), 7 metastatic breast cancer patients harboring only ATM mutations were not responded to olaparib treatment (SD: n=2, PD: n=5)[22].In a phase II trial (TRITON2; NCT02952534), 49 mCRPC patients harboring ATM alteration had limited response to rucaparib treatment. The radiographic response rate was 10.5 % (n=2/19 evaluable patients), the prostate-specific antigen response rate was 4.1% (n=2/49), and the 6-month clinical benefit rate was 28.6% (n=12/42)[23].

In preclinical studies, cells with ATM alternation were sensitive to olaparib, niraparib, and talazoparib treatment in vitro and in vivo[24][25][26][27].

In addition, ATM has been determined as an inclusion criterion for the trials evaluating olaparib efficacy in breast cancer (NCT04053322) and advanced solid tumors (NCT03297606), rucaparib efficacy in ovarian cancer (NCT01968213)[28]and prostate cancer (NCT02952534, NCT03533946)[23], niraparib efficacy in pancreatic cancer (NCT03553004, NCT03601923), prostate cancer (NCT02854436), melanoma (NCT03925350), metastatic esophageal/gastroesophageal junction (GEJ)/proximal gastric adenocarcinoma (NCT03840967), and any malignancy, except prostate (NCT03207347), and talazoparib efficacy in advanced or metastatic cancer (NCT02286687), HER2-negative solid tumors (NCT02401347), prostate cancer (NCT03148795), and lung cancer (NCT03377556), respectively.

Also, a prospective study in muscle-invasive bladder cancer patients suggested that genomic alternations in the DNA repair genes ATMs, RB1 and FANCC could be recognized as biomarkers predictive of response to cisplatin-based neoadjuvant chemotherapy[29]. However, loss-of-function of the ATM-CHEK2-TP53 cascade is associated with resistance to anthracycline/mitomycin-containing chemotherapy in patients with breast cancer[30].

A retrospective study of VICTOR trial demonstrated that ATM loss was associated with worse prognosis in colorectal cancer[31].

CARD11 Amplification

Biological Impact

CARD11 (caspase recruitment domain 11) gene encodes a cytoplasmic scaffold protein of the CARD11/BCL10/MALT1 (CBM) complex which plays essential roles in regulating apoptosis and NF-κB activation in response to upstream stimuli[32][33]. CARD11 gain-of-function mutations are frequently detected in human diffuse large B-cell lymphoma (DLBCL)[34]and cutaneous squamous cell carcinoma[35]. Moreover, CARD11 gene amplification has been observed in a significant proportion of DLBCL[36]. Biochemical assays revealed that enforced expression of CARD11/BCL10/MALT1 is essential for transformation of B-cell and survival of DLBCL cell[37].

Therapeutic and prognostic relevance

Retrospective studies have shown that high CARD11 expression or CARD11 gene amplification was associated with poor survival in diffuse large B cell lymphoma (DLBCL)[38][36].

TERT Amplification

Biological Impact

The TERT gene encodes the catalytic subunit of telomerase, an enzyme that maintains telomere length and genomic integrity[39]. Upregulation of TERT promotes cancer development and progression via modulation of Wnt-catenin and nuclear factor kappa B signaling[40][41], and mitochondrial RNA processing[42]. Activating mutations in the TERT promoter have been identified in a number of cancer types including melanoma, hepatocellular carcinoma, urothelial carcinoma, medulloblastoma, and glioma whereas TERT gene amplification is implicated in lung cancer, cervical cancer, breast cancer, Merkel cell carcinoma, neuroblastoma and adrenocortical carcinoma[43][44][45][46][47].

Therapeutic and prognostic relevance

Imetelstat (GRN163L), a telomere inhibitor which has been shown to inhibit cell proliferation in various cancer cell lines and tumor xenografts is currently in clinical trials[39].

TERT gene amplification is an independent poor prognostic marker for disease-free survival in non-small cell lung cancer (NSCLC) and breast cancer[48][49][50].

ACT Onco® + Report

US FDA-APPROVED DRUG(S)

Niraparib (ZEJULA)

Niraparib is an oral, small molecule inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1 and -2 (PARP-1, -2). Niraparib is developed and marketed by Tesaro under the trade name ZEJULA.

- FDA Approval Summary of Niraparib (ZEJULA)

PRIMA NCT02655016	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2020/04/29)
	-
	Niraparib vs. Placebo [PFS (overall population)(M): 13.8 vs. 8.2]
NOVA[51] NCT01847274	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2017/03/27)
	-
	Niraparib vs. Placebo [PFS (overall population)(M): 11.3 vs. 4.7]

Olaparib (LYNPARZA)

Olaparib is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase-1, -2, and -3 (PARP-1, -2, -3). Olaparib is developed by KuDOS Pharmaceuticals and marketed by AstraZeneca under the trade name LYNPARZA.

- FDA Approval Summary of Olaparib (LYNPARZA)

OlympiA NCT02032823	**Her2-negative high-risk early breast cancer** (Approved on 2022/03/11)
	HER2-/gBRCA mutation
	Olaparib vs. Placebo [invasive disease-free survival (IDFS)(M):]
PROfound[17] NCT02987543	**Prostate cancer** (Approved on 2020/05/19)
	HRR genes mutation
	Olaparib vs. Enzalutamide or abiraterone acetate [PFS(M): 5.8 vs. 3.5]
PAOLA-1[52] NCT02477644	**Ovarian cancer** (Approved on 2020/05/08)
	HRD+
	Olaparib + bevacizumab vs. Placebo + bevacizumab [PFS(M): 37.2 vs. 17.7]
POLO[53] NCT02184195	**Pancreatic adenocarcinoma** (Approved on 2019/12/27)
	gBRCA mutation
	Olaparib vs. Placebo [ORR(%): 23.0 vs. 12.0, PFS(M): 7.4 vs. 3.8]
SOLO-1[54] NCT01844986	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2018/12/19)
	gBRCA mutation or sBRCA mutation
	Olaparib vs. Placebo [PFS(M): NR vs. 13.8]
OlympiAD[55] NCT02000622	**Breast cancer** (Approved on 2018/02/06)
	HER2-/gBRCA mutation
	Olaparib vs. Chemotherapy [PFS(M): 7 vs. 4.2]
SOLO-2/ENGOT-Ov21[56] NCT01874353	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2017/08/17)
	gBRCA mutation
	Olaparib vs. Placebo [PFS(M): 19.1 vs. 5.5]
Study19[57] NCT00753545	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2017/08/17)
	-
	Olaparib vs. Placebo [PFS(M): 8.4 vs. 4.8]

Rucaparib (RUBRACA)

Rucaparib is an inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1, -2 and -3 (PARP-1, -2, -3). Rucaparib is developed and marketed by Clovis Oncology under the trade name RUBRACA.

- FDA Approval Summary of Rucaparib (RUBRACA)

TRITON2 NCT02952534	**Prostate cancer** (Approved on 2020/05/15)
	gBRCA mutation or sBRCA mutation
	Rucaparib [ORR(%): 44.0, DOR(M): NE]
ARIEL3[28] NCT01968213	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2018/04/06)
	-
	Rucaparib vs. Placebo [PFS (All)(M): 10.8 vs. 5.4, PFS (HRD)(M): 13.6 vs. 5.4, PFS (tBRCA)(M): 16.6 vs. 5.4]

Talazoparib (TALZENNA)

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2. Talazoparib is developed and marketed by Pfizer under the trade name TALZENNA.

- FDA Approval Summary of Talazoparib (TALZENNA)

EMBRACA[58] NCT01945775	**Breast cancer** (Approved on 2018/10/16)
	HER2-/gBRCA mutation
	Talazoparib vs. Chemotherapy [PFS(M): 8.6 vs. 5.6]

D=day; W=week; M=month

ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit https://clinicaltrials.gov to search and view for a complete list of open available and updated matched trials.

No trial has been found.

ACT Onco® + Report

SUPPLEMENTARY INFORMATION OF TESTING RESULTS

DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
Not Detected							

- Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



詹子文
Project ID: C23-M001-00457
Report No.: AA-23-00943_ONC
Date Reported: Feb 24, 2023

OTHER DETECTED VARIANTS

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
ATM	H42R	3	c.125A>G	NM_000051	COSM7325226	59.5%	79
CCNB3	R1113W	6	c.3337C>T	NM_033031	COSM5519871	99.3%	281
CSF1R	S686_P693del	15	c.2056_2079del	NM_005211	-	43.5%	1387
CYLD	T311M	8	c.932C>T	NM_015247	-	48.9%	683
FAT1	A4224T	25	c.12670G>A	NM_005245	-	47.6%	1501
FLT1	T868M	19	c.2603C>T	NM_002019	-	11.8%	466
PIK3C2B	I1178T	25	c.3533T>C	NM_002646	-	49.8%	1784

Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

ACTOnco® + Report

TEST DETAILS

SPECIMEN RECEIVED AND PATHOLOGY REVIEW





- Collection date: Jan 16, 2023
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S11290163A
- Collection site: Stomach
- Examined by: Dr. Yun-An Chen
    1. The percentage of viable tumor cells in total cells in the whole slide (%): 40%
    2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 70%
    3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 0%
    4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%
    5. Additional comment: NA
- Manual macrodissection: Not performed
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

RUN QC

- Panel: ACTOnco®+

DNA test

- Mean Depth: 781x
- Target Base Coverage at 100x: 93%

RNA test

- Average unique RNA Start Sites per control GSP2: 115

ACT Onco® + Report

LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

NEXT-GENERATION SEQUENCING (NGS) METHODS

DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage ≥ 20, allele frequency ≥ 5% and actionable variants with allele frequency ≥ 2% were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at 100x ≥ 85% with a mean coverage ≥ 500x.

Variants reported in Genome Aggregation database with > 1% minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:
Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation ≥ 0.3 were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco®+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as “TMB-High”, “TMB-Low” or “Cannot Be Determined”. TMB-High corresponds to ≥ 7.5 mutations per megabase (Muts/Mb); TMB-Low corresponds to < 7.5 Muts/Mb. TMB is reported as “Cannot Be Determined” if the tumor purity of the sample is < 30%.

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in > 400 genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be ≥ 10.

ACT Onco® + Report

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2 ≥ 3; (2) Number of supporting reads spanning the fusion junction ≥ 5; (3) Percentage of supporting reads spanning the fusion junction ≥ 10%; (4) Fusions annotated in Quiver Gene Fusion Database.

DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

Variant Analysis:
醫藥資訊研究員
楊杭哲 博士
Hang-Che Yang Ph.D.

Sign Off
解剖病理專科醫師王業翰
Yeh-Han Wang M.D.
病解字第 000545 號

ACT Onco® + Report

GENE LIST

SNV & CNV

ABCB1*	ABCC2*	ABCG2*	ABL1	ABL2	ADAMTS1	ADAMTS13	ADAMTS15	ADAMTS16	ADAMTS18	ADAMTS6	ADAMTS9
ADAMTSL1	ADGRA2	ADH1C*	AKT1	AKT2	AKT3	ALDH1A1*	ALK	AMER1	APC	AR	ARAF
ARID1A	ARID1B	ARID2	ASXL1	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL
B2M	BAP1	BARD1	BCL10	BCL2*	BCL2L1	BCL2L2*	BCL6	BCL9	BCOR	BIRC2	BIRC3
BLM	BMPR1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2*	BTK	BUB1B	CALR
CANX	CARD11	CASP8	CBFB	CBL	CCNA1	CCNA	CCNB1	CCNB2	CCNB3	CCND1	CCND2
CCND3	CCNE1	CCNE2	CCNH	CD19	CD274	CD58	CD70*	CD79A	CD79B	CDC73	CDH1
CDK1	CDK12	CDK2	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDKN1A	CDKN1B	CDKN2A
CDKN2B	CDKN2C	CEBPA*	CHEK1	CHEK2	CIC	CREBBP	CRKL	CRLF2	CSF1R	CTCF	CTLA4
CTNNA1	CTNNB1	CUL3	CYLD	CYP1A1*	CYP2B6*	CYP2C19*	CYP2C8*	CYP2D6	CYP2E1*	CYP3A4*	CYP3A5*
DAXX	DCUN1D1	DDR2	DICER1	DNMT3A	DOT1L	DPYD	DTX1	E2F3	EGFR	EP300	EPCAM
EPHA2	EPHA3	EPHA5	EPHA7	EPHB1	ERBB2	ERBB3	ERBB4	ERCC1	ERCC2	ERCC3	ERCC4
ERCC5	ERG	ESR1	ESR2	ETV1	ETV4	EZH2	FAM46C	FANCA	FANCC	FANCD2	FANCE
FANCF	FANCG	FANCL	FAS	FAT1	FBXW7	FCGR2B	FGF1*	FGF10	FGF14	FGF19*	FGF23
FGF3	FGF4*	FGF6	FGFR1	FGFR2	FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FLT4
FOXL2*	FOXP1	FRG1	FUBP1	GATA1	GATA2	GATA3	GNA11	GNA13	GNAQ	GNAS	GREM1
GRIN2A	GSK3B	GSTP1*	GSTT1*	HGF	HIF1A	HIST1H1C*	HIST1H1E*	HNF1A	HR	HRAS*	HSP90AA1
HSP90AB1	HSPA4	HSPA5	IDH1	IDH2	IFNL3*	IGF1	IGF1R	IGF2	IKBKB	IKBKE	IKZF1
IL6	IL7R	INPP4B	INSR	IRF4	IRS1	IRS2*	JAK1	JAK2	JAK3	JUN*	KAT6A
KDM5A	KDM5C	KDM6A	KDR	KEAP1	KIT	KMT2A	KMT2C	KMT2D	KRAS	LCK	LIG1
LIG3	LMO1	LRP1B	LYN	MALT1	MAP2K1	MAP2K2	MAP2K4	MAP3K1	MAP3K7	MAPK1	MAPK3
MAX	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MET	MITF	MLH1	MPL	MRE11
MSH2	MSH6	MTHFR*	MTOR	MUC16	MUC4	MUC6	MUTYH	MYC	MYCL	MYCN	MYD88
NAT2*	NBN	NEFH	NF1	NF2	NFE2L2	NFKB1	NFKBIA	NKX2-1*	NOTCH1	NOTCH2	NOTCH3
NOTCH4	NPM1	NQO1*	NRAS	NSD1	NTRK1	NTRK2	NTRK3	PAK3	PALB2	PARP1	PAX5
PAX8	PBRM1	PDCD1	PDCD1LG2	PDGFRA	PDGFRB	PDIA3	PGF	PHOX2B*	PIK3C2B	PIK3C2G	PIK3C3
PIK3CA	PIK3CB	PIK3CD	PIK3CG	PIK3R1	PIK3R2	PIK3R3	PIM1	PMS1	PMS2	POLB	POLD1
POLE	PPARG	PPP2R1A	PRDM1	PRKAR1A	PRKCA	PRKCB	PRKCG	PRKCI	PRKCQ	PRKDC	PRKN
PSMB8	PSMB9	PSME1	PSME2	PSME3	PTCH1	PTEN	PTGS2	PTPN11	PTPRD	PTPRT	RAC1
RAD50	RAD51	RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	RECQL4
REL	RET	RHOA	RICTOR	RNF43	ROS1	RPPH1	RPTOR	RUNX1	RUNX1T1	RXRA	SDHA
SDHB	SDHC	SDHD	SERPINB3	SERPINB4	SETD2	SF3B1	SGK1	SH2D1A*	SLC19A1*	SLC22A2*	SLCO1B1*
SLCO1B3*	SMAD2	SMAD3	SMAD4	SMARCA4	SMARCB1	SMO	SOCS1*	SOX2*	SOX9	SPEN	SPOP
SRC	STAG2	STAT3	STK11	SUFU	SYK	SYNE1	TAF1	TAP1	TAP2	TAPBP	TBX3
TEK	TERT	TET1	TET2	TGFBR2	TMSB4X*	TNF	TNFAIP3	TNFRSF14	TNFSF11	TOP1	TP53
TPMT*	TSC1	TSC2	TSHR	TYMS	U2AF1	UBE2A*	UBE2K	UBR5	UGT1A1*	USH2A	VDR*
VEGFA	VEGFB	VHL	WT1	XIAP	XPO1	XRCC2	ZNF217				

*Analysis of copy number alterations NOT available.

FUSION

ALK	BRAF	EGFR	FGFR1	FGFR2	FGFR3	MET	NRG1	NTRK1	NTRK2	NTRK3	RET	ROS1

詹子文
Project ID: C23-M001-00457
Report No.: AA-23-00943_ONC
Date Reported: Feb 24, 2023

APPENDIX

POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION

Gene	Therapies	Possible effect
ATM	Niraparib, Olaparib, Rucaparib, Talazoparib	**sensitive**

SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS



1: Olaparib, Niraparib, Rucaparib, Talazoparib

ACT Onco® + Report

DISCLAIMER

法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。
本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。
本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

ACT Onco® + Report

REFERENCE

1. PMID: 22079189; 2012, Trends Biochem Sci;37(1):15-22
The ATM protein kinase and cellular redox signaling: beyond the DNA damage response.

2. PMID: 1548942; 1992, Leukemia;6 Suppl 1():8-13
Cancer susceptibility in ataxia-telangiectasia.

3. PMID: 12810666; 2003, Cancer Res;63(12):3325-33
Contributions of ATM mutations to familial breast and ovarian cancer.

4. PMID: 1961222; 1991, N Engl J Med;325(26):1831-6
Incidence of cancer in 161 families affected by ataxia-telangiectasia.

5. PMID: 28779002; 2017, J Med Genet;54(11):732-741
Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks.

6. PMID: 16400190; 2006, Carcinogenesis;27(4):848-55
Atm-haploinsufficiency enhances susceptibility to carcinogen-induced mammary tumors.

7. PMID: 29478780; 2018, Am J Hum Genet;102(3):401-414
Inherited DNA-Repair Defects in Colorectal Cancer.

8. PMID: 9488043; 1998, Oncogene;16(6):789-96
ATM is usually rearranged in T-cell prolymphocytic leukaemia.

9. PMID: 11429421; 2001, J Clin Pathol;54(7):512-6
Ataxia telangiectasia gene mutations in leukaemia and lymphoma.

10. PMID: 11756177; 2002, Blood;99(1):238-44
ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.

11. PMID: 21993670; 2012, Haematologica;97(1):47-55
ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.

12. PMID: 22981675; 2013, Eur Urol;63(5):920-6
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

13. PMID: 22410096; 2012, Oral Oncol;48(8):698-702
Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma.

14. PMID: 23103869; 2012, Nature;491(7424):399-405
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.

15. PMID: 18948947; 2008, Nature;455(7216):1069-75
Somatic mutations affect key pathways in lung adenocarcinoma.

16. PMID: 30537493; 2019, Hum Pathol;86():85-92
Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.

17. PMID: 32343890; 2020, N Engl J Med;382(22):2091-2102
Olaparib for Metastatic Castration-Resistant Prostate Cancer.

18. PMID: 26510020; 2015, N Engl J Med;373(18):1697-708
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

19. PMID: 31806540; 2020, Lancet Oncol;21(1):162-174
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-

label, randomised, phase 2 trial.

20. PMID: 26282658; 2015, J Clin Oncol;33(33):3858-65
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.

21. PMID: 29103871; 2017, Lancet Oncol;18(12):1637-1651
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.

22. PMID: 33119476; 2020, J Clin Oncol;38(36):4274-4282
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.

23. PMID: 32086346; 2020, Clin Cancer Res;26(11):2487-2496
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.

24. PMID: 20739657; 2010, Blood;116(22):4578-87
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

25. PMID: 31699977; 2019, Nat Commun;10(1):5065
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.

26. PMID: 34503215; 2021, Cancers (Basel);13(17):
Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress.

27. PMID: 23881923; 2013, Clin Cancer Res;19(18):5003-15
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.

28. PMID: 28916367; 2017, Lancet;390(10106):1949-1961
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

29. PMID: 26238431; 2015, Eur Urol;68(6):959-67
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.

30. PMID: 22420423; 2012, Breast Cancer Res;14(2):R47
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

31. PMID: 23154512; 2012, Oncotarget;3(11):1348-55
Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN.

32. PMID: 11278692; 2001, J Biol Chem;276(15):11877-82
CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B.

33. PMID: 26260210; 2015, Mol Immunol;68(2 Pt C):546-57
TCR signaling to NF-κB and mTORC1: Expanding roles of the CARMA1 complex.

34. PMID: 18323416; 2008, Science;319(5870):1676-9
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.

35. PMID: 26212909; 2015, Am J Pathol;185(9):2354-63
Novel CARD11 Mutations in Human Cutaneous Squamous Cell Carcinoma Lead to Aberrant NF-κB Regulation.

36. PMID: 22397314; 2012, Leuk Lymphoma;53(10):1971-7
Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.

37. PMID: 26668357; 2015, Proc Natl Acad Sci U S A;112(52):E7230-8
Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.

38. PMID: 26876250; 2016, Zhonghua Xue Ye Xue Za Zhi;37(1):30-4
[Expression and prognostic value of CARD11 in diffuse large B cell lymphoma].

39. PMID: 21332640; 2011, J Cell Mol Med;15(7):1433-42
Targeting telomerase-expressing cancer cells.

40. PMID: 19571879; 2009, Nature;460(7251):66-72
Telomerase modulates Wnt signalling by association with target gene chromatin.

41. PMID: 23159929; 2012, Nat Cell Biol;14(12):1270-81
Telomerase directly regulates NF-κB-dependent transcription.

42. PMID: 19701182; 2009, Nature;461(7261):230-5
An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA.

43. PMID: 23348506; 2013, Science;339(6122):957-9
Highly recurrent TERT promoter mutations in human melanoma.

44. PMID: 23530248; 2013, Proc Natl Acad Sci U S A;110(15):6021-6
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

45. PMID: 11103775; 2000, Cancer Res;60(22):6230-5
Frequent amplification of the telomerase reverse transcriptase gene in human tumors.

46. PMID: 12007187; 2002, Genes Chromosomes Cancer;34(3):269-75
Amplification of the telomerase reverse transcriptase (hTERT) gene in cervical carcinomas.

47. PMID: 25301727; 2014, Oncotarget;5(20):10048-57
TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma.

48. PMID: 16641908; 2006, Br J Cancer;94(10):1452-9
Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer.

49. PMID: 27982019; 2017, Cancer Gene Ther;24(1):20-27
The associations of TERT-CLPTM1L variants and TERT mRNA expression with the prognosis of early stage non-small cell lung cancer.

50. PMID: 29100407; 2017, Oncotarget;8(44):77540-77551
TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer.

51. PMID: 27717299; 2016, N Engl J Med;375(22):2154-2164
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

52. PMID: 31851799; 2019, N Engl J Med;381(25):2416-2428
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

53. PMID: 31157963; 2019, N Engl J Med;381(4):317-327
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

54. PMID: 30345884; 2018, N Engl J Med;379(26):2495-2505
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

55. PMID: 28578601; 2017, N Engl J Med;377(6):523-533
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

56. PMID: 28754483; 2017, Lancet Oncol;18(9):1274-1284
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

ACT Onco® + Report

57. PMID: 27617661; 2016, Lancet Oncol;17(11):1579-1589
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

58. PMID: 30110579; 2018, N Engl J Med;379(8):753-763
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.